Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- Drug: Nadroparin, long term
- Registration Number
- NCT01980849
- Lead Sponsor
- Shengqing Li
- Brief Summary
To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.
- Detailed Description
This is a prospective, multi-center, randomized and controlled study. Advanced lung cancer patients without venous thromboembolism(VTE) are included. The selected patients were randomized into A and B groups. Group A: Nadroparin given during hospitalization, 0.4mL, subcutaneously, qid; Group B: Nadroparin given by long-term, 0.4mL, subcutaneously, qid. The incidence of VTE , the risks of bleeding and overall survival in two groups of patients are studied at different time points.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 272
- Stage Ⅲ B and Ⅳ non-small cell lung cancer patients and inoperable small cell lung cancer patients
- Performance status score ≤ 2
- Chest CT with measurable lesions
- Examination revealed any part of venous thromboembolism
- Chemotherapy regimens containing bevacizumab or Endostar
- Severe coagulopathy
- Active bleeding within two weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Long term prophylaxis Nadroparin, long term Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
- Primary Outcome Measures
Name Time Method Incidence of venous thromboembolism 12 weeks
- Secondary Outcome Measures
Name Time Method Incidence of bleeding During 6 months
Trial Locations
- Locations (23)
The Department of Pulmonary and Critical Care Medicine,Cancer Hospital
🇨🇳Zhengzhou, Henan, China
The Department of Oncology，Henan University Affiliated Yihe Hospital
🇨🇳Zhengzhou, Henan, China
The Department of Oncology，Cancer Hospital
🇨🇳Baotou, Inner Mongolia, China
The Department of Oncology，Inner Mongolia Autonomous Region Hospital
🇨🇳Hohhot, Inner Mongolia, China
The Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital of Jiaotong University
🇨🇳Xi'an, Shaanxi, China
The Department of Pulmonary and Critical Care Medicine,Second People's Hospital
🇨🇳Xi'an, Shaanxi, China
The Department of Oncology，Yan'an University Hospital
🇨🇳Yan'an, Shaanxi, China
The Department of Oncology，Second Hospital of Shanxi Medical University
🇨🇳Taiyuan, Shanxi, China
The Department of Pulmonary and Critical Care Medicine,First Affiliated Hospital of Medical University
🇨🇳Urumqi, Xinjiang, China
The Department of Oncology，Northern Hospital
🇨🇳Baotou, Inner Mongolia, China
The Department of Pulmonary and Critical Care Medicine, Tangdu Hospital
🇨🇳Xi'an, Shaanxi, China
The Department of Oncology，First Affiliated Hospital of Jiaotong University
🇨🇳Xi'an, Shaanxi, China
The Department of Pulmonary and Critical Care Medicine,Southwest Hospital
🇨🇳Chongqing, Chongqing, China
The Department of Oncology，Ohtsubo Hospital
🇨🇳Chongqing, Chongqing, China
The Department of Oncology，Southwest Hospital
🇨🇳Chongqing, Chongqing, China
The Department of Oncology，Central Hospital
🇨🇳Xinxiang, Henan, China
The Department of Oncology，Fuling Central Hospital
🇨🇳Chongqing, Chongqing, China
The Department of Oncology，People's Hospital
🇨🇳Chengdu, Sichuan, China
The Department of Pulmonary and Critical Care Medicine,Central Hospital
🇨🇳Baoji, Shaanxi, China
The Department of Pulmonary and Critical Care Medicine,Medical University General Hospital cardiovascular and cerebrovascular disease hospital
🇨🇳Yinchuan, Ningxia, China
The Department of Pulmonary and Critical Care Medicine, Xijing Hospital
🇨🇳Xi'an, Shaanxi, China
The Department of Lung oncology，Tumor Hospital
🇨🇳Chengdu, Sichuan, China
The Department of Oncology，First Affiliated Hospital of Medical University
🇨🇳Urumqi, Xinjiang, China